Silvant Capital Management LLC Takes Position in Stryker Corporation $SYK

Key Points

• Silvant Capital Management initiated a Stryker position in the second quarter, purchasing 5,152 shares valued at approximately $1.62 million. Institutional investors and hedge funds collectively own 77.09% of SYK.
• Stryker’s latest quarterly results exceeded expectations, with earnings of $3.69 per share and revenue of $6.59 billion, up 9.4% year over year. The company issued fiscal 2026 EPS guidance of $14.95 to $15.10.
• Shares recently opened at $327.97, down 3.5%, while analysts maintain a “Moderate Buy” consensus rating and an average price target of $386.28. Stryker also declared a quarterly dividend of $0.88 per share, yielding about 1.1% annually.

Silvant Capital Management LLC bought a new position in Stryker Corporation (NYSE:SYK - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 5,152 shares of the medical technology company's stock, valued at approximately $1,622,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. VanderPol Investments L.L.C. grew its stake in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after purchasing an additional 28 shares during the last quarter. KCM Investment Advisors LLC raised its stake in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock worth $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock worth $159,000 after purchasing an additional 28 shares during the period. Tcfg Wealth Management LLC boosted its position in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock valued at $403,000 after buying an additional 29 shares during the last quarter. Finally, West Michigan Advisors LLC increased its holdings in Stryker by 0.4% in the 4th quarter. West Michigan Advisors LLC now owns 7,468 shares of the medical technology company's stock worth $2,631,000 after buying an additional 30 shares during the period. Institutional investors and hedge funds own 77.09% of the company's stock.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of Stryker stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at $2,088,423. This represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 665,370 shares of company stock valued at $216,238,501 in the last three months. 4.60% of the stock is currently owned by company insiders.

Stryker Trading Down 3.5%

SYK stock opened at $327.97 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a market cap of $125.80 billion, a P/E ratio of 33.99, a PEG ratio of 2.17 and a beta of 0.76. The company's 50-day simple moving average is $326.64 and its 200-day simple moving average is $332.66.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.Stryker's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's dividend payout ratio is presently 36.48%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on SYK. Truist Financial raised their price target on shares of Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research report on Friday, July 31st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. Raymond James Financial set a $370.00 target price on shares of Stryker in a report on Friday, July 31st. Citizens Jmp decreased their target price on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research report on Monday, August 3rd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source